基本信息

Name: Xiaoran Yin,

Gender: Female

Title: Associate Professor and Deputy Chief Physician, PhD. MD.

EDUCATION & Work

  •  06/2015 - now

Associate Professor and Deputy Chief Physician, Oncology Department of the Second Affiliated Hospital of Xi'an Jiaotong University.

  • 09/2019-12/2020

Visiting Associate Professor, Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA

  • 09/2012 - 06/2017

PhD of Internal Medicine (in-service of the hospital), Xi’an Jiaotong University, Xi’an, China.

  • 06/2008 - 12/2015

Attending Physician and Lecturer, Oncology Department of the Second Affiliated Hospital of Xi'an Jiaotong University.

  • 06/2005 - 06/2008

Resident Physician and Teaching assistant, Oncology Department of the Second Affiliated Hospital of Xi'an Jiaotong University.

  • 09/1997 - 06/2005

MD of Internal Medicine, Xi’an Jiaotong University, Xi’an, China.

PROFESSION SOCIETIES:

  • 2018-present

Integrated Tumor Branch Committee, China Anticancer Association, Association Member.

  • 2018-present

Digestive Tract Tumor Collaborative Group of the Digestive Diseases Committee, Chinese Medical Association. Association Member

  • 2018-present

Chinese Medical Association. Association Member

  • 2021-present

Famous Medicine Academic Research Branch of China Association of Traditional Chinese Medicine

  • 2018-present

Aged cancer Branch Youth Committee, Shaanxi Province Anticancer Association, Vice President

  • 2022-present

Multi-primary and Unknown Primary Tumor Youth Committee, Shaanxi Province Anticancer Association, Vice President

  • 2019-present

Pancreatic Disease Specialist Committee, Shaanxi Provincial Medical Association, Standing Committee Member.

  • 2019-present

Tumor Immunodiagnosis and Treatment Professional Committee, Shaanxi Provincial Medical Association, Standing Committee Member.

  • 2018-present

Anti-cancer Drug Branch Committee, Shaanxi Provincial Medical Association, Standing Committee Member.

联系方式

Address: Oncology Department of the Second Affiliated Hospital of Xi'an Jiaotong University, 157 Xiwu Road, Xi’an, 710004, P. R. China

Email: yinxiaoran@163.com

站点计数器

我的新闻

研究领域

  • Novel tissue- and organ targeted contrast agents and polymer-based nanocarriers for precise theranostics of malignant tumors
  • Combining smart environment-responsive nanoparticle vaccine and precisephotodynamic therapy for targeting cancer stem cells
  • Immunotherapy and related molecular mechanisms, of particular interest on precise tumor vaccines

 

SELECTED PUBLICATIONS

[1]    Xiaoran Yin, Yanan Cui, Richard S. Kim, Wesley R. Stiles, Seung Hun Park, Haoran Wang, Li Ma, Lin Chen, Yoonji Baek, Satoshi Kashiwagi, Kai Bao, Amy Ulumben, Takeshi Fukuda, Homan Kang, and Hak Soo Choi. Image-Guided Drug Delivery of  Nanotheranostics for Personalized Lung Cancer Therapy. Theranostics, 2022; 12(9): 4147-4162. (SCI, IF: 11.556)

[2]   Yin X, Feng C, Han L, Ma Y, Jiao Y, Wang J, Jia L, Jing F, Gao X, Zhang Y, Zhang J*. Diallyl disulfide inhibits the metastasis of type Ⅱ esophageal-gastric junction adenocarcinoma cells via NF-κB and PI3K/AKT signaling pathways in vitro. Oncol Rep, 2018, 39(2): 784-794. (SCI, IF: 3.906)

[3]   Yin X, Zhang R, Feng C, Zhang J, Liu D, Xu K, Wang X, Zhang S, Li Z, Liu X, Ma H*. Diallyl disulfide induces G2/M arrest and promotes apoptosis through the p53/p21 and MEK-ERK pathways in human esophageal squamous cell carcinoma, Oncol Rep, 2014, 32(4): 1748-1756. (SCI, IF: 3.906)

[4]    Yin X#, Zhang J#, Li X, Liu D, Feng C, Liang R, Zhuang K, Cai C, Xue X, Jing F, Wang X, Wang J, Liu X, Ma H*. DADS suppresses human esophageal xenograft tumors through RAF/MEK/ERK and mitochondria-dependent pathways, Int J Mol Sci, 2014, 15(7): 12422-12441. (SCI, IF: 5.923)

[5]   Yin XR, Zhang M, Luo YY, Lin X, He PC, Chen LM, Cai RB, Guo GL. Induction of active antitumor immune response by myeloma idiotype protein-pulsed dendritic cells. Ai Zheng. 2005, 24(6): 657-662. Chinese. (Medline)

[6]    H. Kang, M. Shamim, X. Yin, E. Adluru, T. Fukuda, S. Yokomizo, H. Chang, S.H. Park, Y. Cui, A.J. Moy, S. Kashiwagi, M. Henary, H.S. Choi, Tumor-Associated Immune-Cell-Mediated Tumor-Targeting Mechanism with NIR-II Fluorescence Imaging, Adv Mater, 34 (2022) e2106500. （SCI, IF:30.5）

[7]   Zhang R, Yin X, Shi H, Wu J, Shakya P, Liu D, Zhang J*, Adiponectin Modulates Inflammatory Factors Expression Induced by Deoxycholic Acid via Reactive Oxygen Species in Esophageal Adenocarcinoma Cells, Gastroenterology, 2013, 144(5): S-675. （SCI, IF:22.68）

[8]   Zhang M，Yin XR，Luo YY，Lin X，Wang MC，He PC，Li J，Guo GL，Cai RH，Liu YL. In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine, Zhonghua Xue Ye Xue Za Zhi. 2005, 26(10): 593-597.Chinese. (Medline, tutor first)

[9]    H. Kang, M. Shamim, X. Yin, E. Adluru, T. Fukuda, S. Yokomizo, H. Chang, S.H. Park, Y. Cui, A.J. Moy, S. Kashiwagi, M. Henary, H.S. Choi, Tumor-Associated Immune-Cell-Mediated Tumor-Targeting Mechanism with NIR-II Fluorescence Imaging, Adv Mater, 34 (2022) e2106500. (SCI, IF:30.5)

[10]  Han LL, Yin XR, Zhang SQ*. miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2. Int J Oncol. 2018, 53(6): 2433– 2444. (SCI, IF:5.65)

[11]  Han LL, Yin XR, Zhang SQ*. miR-650 Promotes the Metastasis and Epithelial- Mesenchymal Transition of Hepatocellular Carcinoma by Directly Inhibiting LATS2 Expression. Cell Physiol Biochem. 2018, 51(3):1179–1192. (SCI, IF: 5.581)

[12]  Xiaoran Yin, Hongbing Ma, Xiaoning Li, Zhijun Dai, Xinghuan Xue,Shuqun Zhang,Kaige Liu;,Yan Diao, Yinan Ma, Xijing Wang*. The observation of single-agent gemcitabine maintenance therapy in patients with metastatic breast cancer, Chinese-German Journal of Clinical Oncology, 2013, 12(12): 568-573.

[13]  Zhang R, Yin X, Shi H, Wu J, Shakya P, Liu D, Zhang J×. Adiponectin modulates DCA-induced inflammation via the ROS/NF-κ B signaling pathway in esophageal adenocarcinoma cells, Dig Dis Sci, 2014, 59(1): 89-97. (SCI, IF: 2.937)

[14]  S. Zhang, Y. Ma, J. Jiang, Z. Dai, X. Gao, X. Yin, W. Xi, W. Min, Inhibition of urokinase-type plasminogen activator expression by dihydroartemisinin in breast cancer cells, Oncol Lett, 2014; 7: 1375-1380. (SCI, IF: 2.967）

[15]  S. Yu, L. Jing, X.R. Yin, M.C. Wang, Y.M. Chen, Y. Guo, K.J. Nan, L.L. Han, MiR-195 suppresses the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by inhibiting YAP, Oncotarget, 2017, 8: 99757-99771. (SCI,  IF:3.331）

[16]  Feng C, Luo Y, Nian Y, Liu D, Yin X, Wu J, Di J, Zhang R, Zhang J. Diallyl Disulfide Suppresses the Inflammation and Apoptosis Resistance Induced by DCA Through ROS and the NF-κB Signaling Pathway in Human Barrett's Epithelial Cells.  Inflammation. 2017 Jun;40(3):818-831. (SCI, IF:3.923）

[17]  Huang X, Yang Y, Liu Q, Tang X, Shi J, Qu H, Chen X, Gong L, Wang S, Tang S, Wang P, Tang L, Hu D, Yin X, Guan Y, Kong D, Tian F. Prognostic Characteristics of Colorectal Cancer Patients With Benign Mesenteric Lymph Node Enlargement: A  Multi-Institutional Cohort Study. Dis Colon Rectum. 2021 Nov 8. (SCI, IF:3.519）

[18]  Ma H, Zheng S, Zhang X, Gong T, Lv X, Fu S, Zhang S, Yin X, Hao J, Shan C, Huang S. High mobility group box 1 promotes radioresistance in esophageal squamous cell carcinoma cell lines by modulating autophagy. Cell Death Dis. 2019 Feb 12; 10(2): 136. (SCI, IF:8.469）

[19]  Jing FC, Zhang J, Feng C, Nian YY, Wang JH, Hu H, Yang BD, Sun XM, Zheng JY, Yin XR. Potential rat model of anxiety-like gastric hypersensitivity induced by sequential stress. World J Gastroenterol. 2017 Nov 14;23(42):7594-7608. (SCI, IF: 5.742）

[20]  Jia L, Huang S, Yin X, Zan Y, Guo Y, Han L. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sci. 2018 Sep 1; 208:123-130. (SCI, IF:5.037）

[21]  Wang J, Cheng Y, Yin X, Wu J, Luo Y, Wu J, Di J, Liu D, Huang Y, Zhang R, Zhang J. Globular adiponectin inhibits leptin-stimulated esophageal adenocarcinoma cell proliferation via adiponectin receptor 2-mediated suppression of UHRF1. Mol Cell Biochem. 2017 Jul;431(1-2):103-112. (SCI, IF:3.396）

 

FUNDS

[1]  National Natural Science Foundation of China，Experimental Study of Combining Smart Environment-responsive Nanoparticle Vaccine and Precise Photodynamic Therapy for Targeting Gastric Cancer Stem Cells (Host，Grant No. 81802453).

[2]   Science and Technology Research Foundation of Shannxi Province ， Study of Isolation and Identification of Cardiac Cancer Stem Cells (Host ，Grant No. 2011K13-02-05).

[3]   National Natural Science Foundation of China，Research for Mechanism of Tumor Exosomes miRNA Regulating Treg Cells in Radioresistance of Esophageal Squamous Cell Carcinoma (Second participant，Grant No. 81872471).

[4]   National Natural Science Foundation of China，Research for the dynamic regulation of protein kinase function based on environment-responsive molecular block library. (Second participant，Grant No. 92053103).

[5]    National Natural Science Foundation of China ， Study based on subcellular comparative proteomics on the mechanism of inhibiting breast cancer metastasis of Chinese medicine Huangqi and Huanglian (Main participant，Grant No. 81274136).

[6]    National Natural Science Foundation of China，Study on induction of antigen-specific CTL by human myeloma protein antigen-expressing peptide (Second participant， Grant No. 3017388).

CONFERENCES

  • Talks: Xiaor an Yin, “Barrett’s esophagus and its correlation with gastroesophageal reflux in Chinese”, World Gastroenterology & Hepatology Conference, Rome, Italy, September 2018 (Invited Talk, 30 minutes)

PATENTS

  • An Automatic Processing Device for Traditional Chinese Medicine, ZL201721646761. X., The Second Affiliated Hospital of Xi’an Jiaotong University
  • A Medicinal Grinding Device for Oncology Dispensing, ZL201720530552.2., The Second Affiliated Hospital of Xi’an Jiaotong University

TREATISES

  • Xiaoran Yin (Associate editor), Barrett’s Esophagus and Adenocarcinoma, People’s Medical Publishing House, 2011.
  • Xiaoran Yin (Participate editor), Differential Diagnosis of Digestive Diseases, Science Press, 2009.

EDITOR

Ø 2022-present

Frontiers in Oncology, IF:6.244, Guest top editor of special issue.

REVIEWER

  • 2019-present

International Journal of Molecular Sciences (IJMS), IF:5.923, Reviewer

  • 2022-present

Frontiers in Bioscience-Landmark (FBL), IF:4.009, Reviewer

  • 2019-present

Oncology Reports (OR), IF:3.906, Reviewer

  • 2015-present

Journal of pharmacy and pharmacology (JPP), IF:3.765,Reviewer